Drug intelligence / Profile preview

bufonosterol

Development stage: Preclinical
Lead developer: Hefei Huafang Pharmaceutical Technology
Modality: Small Molecules

Overview

Bufonosterol (蟾蜍甾烯总内酯) is a Class 1 new Traditional Chinese Medicine (TCM) drug candidate developed by Hefei Huafang Pharmaceutical Technology. It is a natural product extract derived from toad secretions, primarily composed of toad steroid lactones (bufadienolides). The drug is currently in the preclinical/research stage of development, with investigations focused on its anti-tumor activity across various cancer types. Additionally, it has been mentioned in research contexts related to COVID-19. While its broad anti-tumor properties have been reported, the specific molecular targets and detailed mechanism of action have not been publicly disclosed by the developer.

Other names: 蟾蜍甾烯总内酯Toad steroid lactone

Beyond the preview

Go deeper on bufonosterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bufonosterol.

Explore the full profile